Bempedoic Acid Pregnancy Surveillance Program

Condition(s) studied

Investigational drug(s) / intervention(s)

Bempedoic Acid: Bempedoic Acid 180 MG

Bempedoic Acid / Ezetimibe: Bempedoic Acid 180 MG / Ezetimibe 10 MG

Study summary

Bempedoic acid pregnancy surveillance program

Eligibility

Primary outcome measure(s)

• Major congenital malformations (MCM) — Birth up to 12 months
  An abnormality of body structure or function that is present at birth, is of prenatal origin (i.e., birth defect), has significant medical, social, or cosmetic consequences for the affected individual, and typically requires medical intervention (CDC 2019a). MCMs will be defined and coded with criteria specified by US CDC Metropolitan Atlanta Congenital Defects Program (MACDP).

Trial sites (1)

Other trials for the same condition